Autolus FIRST LOOK: Presents additional obe-cel analysis in r/r ALL at EHA

Autolus presented additional analysis for obe-cel in r/r adult ALL at the European Hematology Association (EHA) congress, which included previously presented durability data for obe-cel showing that 40% of patients were in ongoing remission without subsequent therapies at 21.5 months follow up. The new presentations included i) the impact of inotuzumab (INO)-containing bridging therapy on treatment outcomes, and ii) droplet digital PCR and flow cytometry sensitivity for measuring CAR T-cell kinetics. We reiterate our $11 TP and BUY rating.